about
Toxoplasma histone acetylation remodelers as novel drug targetsDrug repurposing and human parasitic protozoan diseasesStructural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoniComputational studies on sirtuins from Trypanosoma cruzi: structures, conformations and interactions with phytochemicalsTargeting Lysine Deacetylases (KDACs) in ParasitesInsecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprinaCombattre les maladies négligées en ciblant sélectivement leurs enzymes épigénétiques : le cas de la désacétylase 8 (HDAC8) de Schistosoma mansoni.Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca spComparative gene expression profiling of P. falciparum malaria parasites exposed to three different histone deacetylase inhibitorsDynamic epigenetic regulation of gene expression during the life cycle of malaria parasite Plasmodium falciparum.Valproic acid as a potential inhibitor of Plasmodium falciparum histone deacetylase 1 (PfHDAC1): an in silico approach.Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasitesAntimalarial activity of the anticancer histone deacetylase inhibitor SB939.Histone deacetylase enzymes as drug targets for the control of the sheep blowfly, Lucilia cuprinaDiscovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACsComparative effects of histone deacetylases inhibitors and resveratrol on Trypanosoma cruzi replication, differentiation, infectivity and gene expression.Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth.Drugs in development for toxoplasmosis: advances, challenges, and current status.Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.Exploration of thiaheterocyclic hHDAC6 inhibitors as potential antiplasmodial agents.Malaria Epigenetics.Structural insights of SIR2rp3 proteins as promising biotargets to fight against Chagas disease and leishmaniasis.Molecular docking and molecular dynamics study on SmHDAC1 to identify potential lead compounds against Schistosomiasis.Target-similarity search using Plasmodium falciparum proteome identifies approved drugs with anti-malarial activity and their possible targets.Improper protein trafficking contributes to artemisinin sensitivity in cells lacking the KDAC Rpd3p.A Fluorescence-Lifetime-Based Binding Assay for Class IIa Histone Deacetylases.Synthesis of aminophenylhydroxamate and aminobenzylhydroxamate derivatives and in vitro screening for antiparasitic and histone deacetylase inhibitory activity.KH-TFMDI, a novel sirtuin inhibitor, alters the cytoskeleton and mitochondrial metabolism promoting cell death in Leishmania amazonensis.Photochromic histone deacetylase inhibitors based on dithienylethenes and fulgimides.Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin.Compounds from African Medicinal Plants with Activities Against Selected Parasitic Diseases: Schistosomiasis, Trypanosomiasis and Leishmaniasis.HDACs and their inhibitors in immunology: teaching anticancer drugs new tricksSAHAquines, Novel Hybrids Based on SAHA and Primaquine Motifs, as Potential Cytostatic and Antiplasmodial AgentsCancer and parasitic infections: similarities and opportunities for the development of new control tools
P2860
Q22305931-6A9B116A-E3F3-4E27-85A4-C6EF1BFF5828Q26999453-AF538BC8-3441-4696-9318-6EDD3E5A2534Q27680126-3991B542-3DC4-4AB8-AE44-6718F7B22FA7Q28539769-E760C7B3-A7C3-45F4-861E-985F5FAA790DQ28548415-13D6431D-24BF-44B7-8BF2-38181BD692E5Q28818731-1D2494C8-22C5-432F-B0A2-AFA933F87979Q30315847-600292F6-6810-4C16-931A-D3478D8E4353Q30684975-D467DEDC-A0DB-4F91-980C-C5E94E623F80Q34181991-EFD1189B-10D4-4350-9059-873F5802A6ABQ34611127-212A0795-2AB3-4BF9-8420-86D5DC98C830Q35139158-9F7FFB3D-C2B1-47B8-BAA8-9E554E6921FEQ35864886-8A8118AE-FA16-4E99-AD67-A8CCB4C944CBQ36086326-474D85F3-ED79-427C-9C5C-7366C97AB4FEQ36841513-3A79F57B-C61C-4828-B002-A2D82FBB5759Q36902765-F3C93B90-5849-4384-9BDF-4D20B1334ED0Q37544742-79428F10-C51A-41EB-94D9-73BFD24E3068Q37591018-3F7F575D-AF8D-4C6E-8561-FE9BFA5DDF62Q37613765-6F0B708A-6BFC-459C-9ECC-14552DC08A28Q38031633-CD0DEDAA-6CD5-4824-BFA1-2EB6EC921509Q38750220-64A5F5FF-53B6-4E72-9DCA-59D682CE6F74Q39188733-17C71BAC-F273-438D-8133-AF5CCE3739B8Q39396789-7F2FB296-72CA-4A3A-A76D-6746CCCBA8FEQ41462661-FA2FFC50-3A63-48FC-A98A-8A340EABBAC5Q46322657-5A0B2066-F3EB-467D-A0E5-58288AB8AB6CQ47884901-64D07E8C-BA71-4697-B626-CB549B5FAFFEQ48178633-837EEF81-BF24-4ED3-A7DC-0F1FF837E6D5Q50136310-FE80862F-CD7E-406F-AC3F-B6C4D205CB44Q52763318-7DCA47D6-3C6B-4B19-BF9C-C87FB7B271B2Q53272199-AFF3574C-6211-498A-887A-C3003A7DE48AQ53693963-169C6DA5-98C8-4562-9B73-83DDF32F8B5DQ55000698-889A9B91-E8AA-4860-9237-AFAE4E41983FQ57080833-A30DCEC1-CFD0-45C9-ABC9-A895B5AE37ABQ58730318-F43BBBC5-4A40-4FC7-87D0-B374E691555EQ58855558-19DCB037-A5BE-4219-95C8-44A1E3C08D66
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
HDAC inhibitors in parasitic diseases.
@en
HDAC inhibitors in parasitic diseases.
@nl
type
label
HDAC inhibitors in parasitic diseases.
@en
HDAC inhibitors in parasitic diseases.
@nl
prefLabel
HDAC inhibitors in parasitic diseases.
@en
HDAC inhibitors in parasitic diseases.
@nl
P2860
P50
P356
P1476
HDAC inhibitors in parasitic diseases.
@en
P2860
P356
10.1038/ICB.2011.97
P577
2011-11-29T00:00:00Z